CA1185178A - Method for purifying interferon - Google Patents
Method for purifying interferonInfo
- Publication number
- CA1185178A CA1185178A CA000406723A CA406723A CA1185178A CA 1185178 A CA1185178 A CA 1185178A CA 000406723 A CA000406723 A CA 000406723A CA 406723 A CA406723 A CA 406723A CA 1185178 A CA1185178 A CA 1185178A
- Authority
- CA
- Canada
- Prior art keywords
- interferon
- purifying
- purifying interferon
- high polymer
- eluant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010050904 Interferons Proteins 0.000 title claims abstract description 66
- 102000014150 Interferons Human genes 0.000 title claims abstract description 65
- 229940079322 interferon Drugs 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 51
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229920000642 polymer Polymers 0.000 claims abstract description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000003463 adsorbent Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 235000002639 sodium chloride Nutrition 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- -1 Acryl Chemical group 0.000 claims description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 3
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 claims description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 3
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000002657 fibrous material Substances 0.000 claims description 3
- 229920002972 Acrylic fiber Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 2
- 229920002466 Dynel Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 229920001617 Vinyon Polymers 0.000 claims description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 claims 2
- 239000004254 Ammonium phosphate Substances 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 235000019289 ammonium phosphates Nutrition 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 238000011084 recovery Methods 0.000 abstract description 9
- 230000000840 anti-viral effect Effects 0.000 abstract description 2
- 239000000872 buffer Substances 0.000 abstract description 2
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 102000003996 Interferon-beta Human genes 0.000 description 12
- 108090000467 Interferon-beta Proteins 0.000 description 12
- 229960001388 interferon-beta Drugs 0.000 description 11
- 239000000835 fiber Substances 0.000 description 9
- 102000006992 Interferon-alpha Human genes 0.000 description 7
- 108010047761 Interferon-alpha Proteins 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 229920002239 polyacrylonitrile Polymers 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920000297 Rayon Polymers 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000002964 rayon Substances 0.000 description 3
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000001064 anti-interferon Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56118865A JPS5821691A (ja) | 1981-07-29 | 1981-07-29 | α−及びβ−インタ−フェロンの精製方法 |
| JP56-118865 | 1981-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1185178A true CA1185178A (en) | 1985-04-09 |
Family
ID=14747035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000406723A Expired CA1185178A (en) | 1981-07-29 | 1982-07-06 | Method for purifying interferon |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4465622A (OSRAM) |
| JP (1) | JPS5821691A (OSRAM) |
| CA (1) | CA1185178A (OSRAM) |
| DE (1) | DE3223087C2 (OSRAM) |
| FR (1) | FR2510409A1 (OSRAM) |
| GB (1) | GB2111061B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5702699A (en) * | 1982-09-23 | 1997-12-30 | Cetus Corporation | Process for the recovery of lipophilic proteins |
| US5385738A (en) * | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
| US4855134A (en) * | 1983-10-14 | 1989-08-08 | Sumitomo Pharmaceuticals Company, Limited | Sustained-release preparation |
| EP0150067A3 (en) * | 1984-01-23 | 1986-12-30 | Takeda Chemical Industries, Ltd. | Stable composition of gamma-interferon |
| JPS60228422A (ja) * | 1984-04-26 | 1985-11-13 | Suntory Ltd | 安定化された生理活性物質製剤 |
| JPS60243028A (ja) * | 1984-04-28 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | インタ−フエロンの可溶化方法 |
| EP0168008A3 (en) * | 1984-07-10 | 1986-12-30 | Takeda Chemical Industries, Ltd. | Stable composition of gamma-interferon |
| WO1986000531A1 (fr) * | 1984-07-10 | 1986-01-30 | Takeda Chemical Industries, Ltd. | Composition a base de gamma-interferon |
| US4873312A (en) * | 1985-04-25 | 1989-10-10 | Amgen | Method for purifying interferon and composition of matter produced thereby |
| DE3628468A1 (de) * | 1986-08-21 | 1988-03-03 | Thomae Gmbh Dr K | Neue applikationsformen fuer (alpha)-interferone |
| CA2024046A1 (en) * | 1989-09-28 | 1991-03-29 | Alberto Ferro | Stabilized leukocyte-interferons |
| ATE117088T1 (de) * | 1990-01-27 | 1995-01-15 | Roland Man Druckmasch | Verfahren und vorrichtung zur messung des alkoholgehalts der feuchtflüssigkeit eines feuchtwerks einer offset-druckmaschine. |
| IT1272252B (it) | 1994-05-16 | 1997-06-16 | Applied Research Systems | Formulazioni liquide di interferone beta |
| US5861174A (en) * | 1996-07-12 | 1999-01-19 | University Technology Corporation | Temperature sensitive gel for sustained delivery of protein drugs |
| US20030190307A1 (en) * | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| US6433144B1 (en) * | 1999-01-12 | 2002-08-13 | Viragen, Inc. | Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods |
| EP1343518B1 (en) * | 2000-11-07 | 2009-07-22 | Novartis Vaccines and Diagnostics, Inc. | Stabilized interferon compositions |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| UY27373A1 (es) * | 2001-07-09 | 2003-02-28 | Schering Ag | Formulaciones de interferón beta-humano |
| US7367961B2 (en) * | 2004-09-10 | 2008-05-06 | Depuy Spine, Inc. | Intradiscal injection of autologous interferon |
| CN113845560A (zh) * | 2020-06-28 | 2021-12-28 | 佛山汉腾生物科技有限公司 | 目的蛋白纯化方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4810232B1 (OSRAM) * | 1970-09-04 | 1973-04-02 | ||
| FR2351665A1 (fr) * | 1976-05-21 | 1977-12-16 | Elf Aquitaine | Procede de purification de preparations possedant notamment une activite interferon, preparations purifiees ainsi obtenues et leur application en tant que medicament |
| NL7605805A (nl) * | 1976-05-28 | 1977-11-30 | Stichting Rega V Z W | Werkwijze voor het zuiveren van interferon. |
-
1981
- 1981-07-29 JP JP56118865A patent/JPS5821691A/ja active Granted
-
1982
- 1982-06-07 US US06/385,872 patent/US4465622A/en not_active Expired - Fee Related
- 1982-06-16 GB GB08217388A patent/GB2111061B/en not_active Expired
- 1982-06-21 DE DE3223087A patent/DE3223087C2/de not_active Expired
- 1982-07-06 CA CA000406723A patent/CA1185178A/en not_active Expired
- 1982-07-29 FR FR8213278A patent/FR2510409A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5821691A (ja) | 1983-02-08 |
| DE3223087C2 (de) | 1985-11-14 |
| DE3223087A1 (de) | 1983-02-17 |
| FR2510409B1 (OSRAM) | 1984-06-22 |
| FR2510409A1 (fr) | 1983-02-04 |
| GB2111061B (en) | 1984-11-21 |
| JPS6254440B2 (OSRAM) | 1987-11-14 |
| GB2111061A (en) | 1983-06-29 |
| US4465622A (en) | 1984-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1185178A (en) | Method for purifying interferon | |
| EP0011435B1 (en) | Method of purification of human fibroblast interferon | |
| US4551271A (en) | Purification of interferon by metal chelate chromatography | |
| CA2220515C (en) | Process for producing erythropoietin containing no animal proteins | |
| CA1210720A (en) | Method for the purification of leucocytosis-promoting factor hemagglutinin (lpf-ha) | |
| EP0094672B1 (en) | Purification method of human interferon | |
| JPS63105694A (ja) | 組換え腫瘍壊死因子の精製 | |
| CA1146468A (en) | Homogeneous fibroblast interferon and method for manufacture thereof | |
| EP0087686A2 (en) | Homogeneous human immune interferon and process therefor | |
| JPH05279396A (ja) | 第ｖｉｉｉ因子の精製法と、それによって得られた調製品 | |
| US5244655A (en) | Process for the purification of recombinant human beta interferon, beta interferon thus purified and pharmaceutical compositions which contain it | |
| US4723000A (en) | Human interferon gamma and interleukin-2 | |
| EP0071647B1 (en) | Process for recovering interferon | |
| Katagiri et al. | One step purification procedure of elastase from pancreatic powder by affinity chromatography | |
| Friesen et al. | [63] Purification of human fibroblast interferon by high-performance liquid chromatography | |
| KR860001150B1 (ko) | 인터페론의 정제법 | |
| WHITMAN JR et al. | Purification of human lymphoblastoid cell-derived interferon-alpha by controlled-pore glass bead adsorption chromatography and molecular sieving | |
| KR920000051B1 (ko) | 재조합 α-인터페론의 정제방법 | |
| EP0446850A2 (en) | Process for purifying recombinant human beta-interferon | |
| JPH0260316B2 (OSRAM) | ||
| JPS61224996A (ja) | マウスインタ−フエロンの精製法 | |
| SU1187835A1 (ru) | Способ аффинной хроматографии биологически активных веществ | |
| JPH02177892A (ja) | ヒト・インターフェロンβの精製法 | |
| JPS61242593A (ja) | ヒト・インタ−フエロンβの精製法 | |
| Táboraký et al. | Can a part of an inducer become incorporated into interferon? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEC | Expiry (correction) | ||
| MKEX | Expiry |